Evogliptin for the treatment option for type 2 diabetes: an update of the literature
- 3 June 2022
- journal article
- other
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 15 (6) , 747-757
Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibitors have been the most widely used for type 2 diabetes (T2D); available worldwide since 2006. DPP-4 inhibitors exert their effects by inhibiting dipeptidyl pep...Keywords
This publication has 54 references indexed in Scilit:
- Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitisExpert Opinion on Drug Safety, 2013
- Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysisDiabetologia, 2013
- Treatment of autoimmune diabetes in NOD mice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibitionDiabetologia, 2012
- Evaluation of the Pharmacokinetics, Food Effect, Pharmacodynamics, and Tolerability of DA-1229, a Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers: First-in-Human StudyClinical Therapeutics, 2012
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based TherapiesGastroenterology, 2011
- The DPP‐4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic dosesBritish Journal of Clinical Pharmacology, 2011
- A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesisDiabetes Research and Clinical Practice, 2011
- A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy SubjectsThe Journal of Clinical Pharmacology, 2009
- Spectrum of Calcific Aortic Valve DiseaseCirculation, 2005
- New developments in the incretin conceptDiabetologia, 1985